Lytix Biopharma presents compelling data in collaboration with research groups at National Cancer Institute and Weill Cornell Medicine, USA.

Oslo, 10 November 2022. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian clinical-stage immune-oncology company, today announces the release of new data describing how LTX-315 treatment activates specific immune cells that are critical for a proper priming of tumor-specific T cells.The data will be presented as a poster at the Society for Immunotherapy of Cancer´s 37th Annual Meeting (SITC 2022) in Boston, USA. The poster entitled “Molecular mechanisms of DC activation by melanoma cells responding to LTX-315” describes how dendritic cells (DCs) can be activated by